Experimental cancer combo enters early human testing

NCT ID NCT07508761

Recruiting now Disease control Sponsor: Nanjing Immunophage Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the combination shrinks tumors. About 52 people will take part. The main focus is safety, but researchers will also check for any anti-cancer activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPG7236 (an experimental oral drug) combined with toripalimab (an immunotherapy injection)
What this could lead to: If successful, this combination could shrink tumors or slow cancer growth in people with advanced solid tumors that have not responded to other treatments.
What could go wrong: This is a very early, small trial (Phase 1/2) with only 52 participants. The main goal is safety, not effectiveness. Side effects could be serious, and the drug may not work against the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Shanghai Gaobo Tumor Hospital
RECRUITING

Shanghai, PuDongXinQu, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.